After Successful Pilot, London Drugs Brings PreVu(R) Skin Cholesterol Testing Into Pharmacy Clinical Services Across Western

After Successful Pilot, London Drugs Brings PreVu(R) Skin Cholesterol Testing 
Into Pharmacy Clinical Services Across Western Canada 
Non-Invasive, No Fasting Test Is First Step When Assessing Risk of
Coronary Artery Disease and Heart Disease 
RICHMOND, BRITISH COLUMBIA -- (Marketwire) -- 02/28/13 -- London
Drugs is proud to be the first in Canada to offer our patients and
customers a non-invasive preview into their cholesterol history and
health through PreVu(R) - a simple skin cholesterol test. 
The PreVu(R) test measures the cholesterol found on the bodies'
largest organ, the skin, where cholesterol is accumulated with age.
The test is conducted on the palm of the hand in less than five
minutes, involves no blood draw, needles or fasting with results
available immediately. 
"We have reviewed the clinical research using this screening
technology and have listened to our pharmacists and customers about
whether this test would assist in one's overall health management,"
said John Tse, London Drugs vice president, pharmacy. "What we
learned is that PreVu(R) can assist to either put a patient's mind at
ease if they score low on the skin cholesterol scale or if scoring
high, the patient needs to see their doctor to have a blood
cholesterol test and further risk assessment conducted." 
While skin cholesterol isn't the same as blood cholesterol, it
provides valuable information when assessing risk of coronary artery
disease (CAD) or heart disease. 
In October 2012, London Drugs partnered with Miraculins Inc. and Pear
Healthcare Solutions to test PreVu(R) as a pilot program in 11 London
Drugs pharmacies. Participants from the pilot program were surveyed
following the test with the following results: 


 
--  Three out of four participants planned to discuss their test results
    with their doctor. 
--  One in two people said they would consider making changes to their
    lifestyle based on the test results.

 
Risk factors for coronary artery disease include: 


 
--  low levels of "good" (HDL, or high density lipoprotein) cholesterol 
--  have high levels of "bad" (LDL) cholesterol 
--  have high blood pressure 
--  are a smoker 
--  have diabetes 
--  lead a sedentary lifestyle 
--  are overweight (particularly if you are obese in the torso or have a
    large waist circumference) 
--  have a family history of heart disease 
--  consume alcohol excessively

 
The PreVu(r) point-of-care (POC) test will launch in London Drugs
pharmacies across Western Canada on March 4, 2013. This test is
incorporated into specially designed CAD risk assessment clinics that
are conducted in-pharmacy and supported by Pear Healthcare Solutions,
a leading provider of in-pharmacy health screening and education to
the Canadian pharmacy community and the exclusive distributor of the
PreVu POC. There is a $24.99 fee to attend this clinic. A
tax-deductible receipt will be issued upon request. 
About The PreVu(R) Non-Invasive Skin Cholesterol Test 
The PreVu(R) Point of Care (POC) Test is a non-invasive, risk
assessment technology designed to measure Skin Cholesterol - an
important new biomarker in assessing risk of coronary artery disease
(CAD). The PreVu POC Test is completely painless, non-invasive,
involves no blood draw or needles, and requires no overnight fasting.
This in vitro diagnostic test is conducted on the palm of the hand in
less than 5 minutes with results being immediately available,
facilitating point of care consultation and a next steps discussion.
Skin Cholesterol is the cholesterol that has been deposited and
diffused into tissue, as opposed to freely circulating in the
bloodstream, and the skin contains approximately 11% of all the
cholesterol found in the human body. Elevated Skin Cholesterol has
been shown in clinical studies to be strongly associated with
significant CAD as measured by treadmill stress testing and coronary
angiography, as well as measured by testing for coronary calcium,
carotid artery thickening, and carotid artery plaque. The PreVu POC
Test does not diagnose the presence or absence of CAD, but helps to
identify patients who may be at higher, hidden risk for CAD by
measuring this new biomarker. For more information visit
www.prevu.com.  
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive tests for unmet clinical
needs. A significant number of promising diagnostic opportunities
remain un-commercialized because of the sizable gap between the
discovery stage, when research institutions are typically involved,
and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. Miraculins is also
advancing a suite of biomarkers to aid in the early detection of the
devastating disease of pregnancy known as preeclampsia. The Company's
preeclampsia program is partnered with Alere Inc. (formerly known as
Inverness Medical Innovations), one of the world's largest diagnostic
companies. For more information visit www.miraculins.com. 
About London Drugs 
Founded in 1945, B.C.-based London Drugs has 77 stores in more than
35 major markets throughout British Columbia, Alberta, Saskatchewan
and Manitoba, including its online store www.londondrugs.com. London
Drugs offers consumers a range of products from digital cameras and
cosmetics to computers and televisions. Renowned for its creative
approach to retailing, the company employs more than 7,500 people
with pharmacy and health care services being the heart of its
business. Committed to innovation and superior customer service,
London Drugs has established itself as a reputable and caring company
and continues to position itself for future growth and development. 
About Pear Healthcare Solutions 
Pear Healthcare Solutions is a privately held company specializing in
the development and implementation of programs to address the
evolving needs of pharmacists in their expanding role of providing
healthcare and disease management services. Pear Healthcare Solutions
offers a number of innovative medical devices and professional
education programs that help pharmacies connect with their patients,
improving their health and wellness. Pear provides distribution,
training and support/education services. For more information visit
www.pearhealthcare.com.
Contacts:
London Drugs
Cynnamon Schreinert
Media Relations
604-802-2733
cynnamon@shaw.ca / @CynnamonS
www.londondrugs.com